Partners Group to reduce PCI Pharma stake as consortium takes majority
Partners Group Private Equity Ltd on Tuesday said its investment manager, Partners Group Holding AG, has agreed to exit its existing stake in PCI Pharma Services and reinvest as a minority shareholder, as part of a new ownership structure led by Bain Capital and Kohlberg & Company.
The transaction values Partners Group Private Equity’s stake in PCI at around €83 million, in line with its most recent carrying value.
Under the deal, Partners Group will reinvest €18 million to retain a minority position in the company and support its next phase of growth.
PCI Pharma, a contract development and manufacturing organisation, has been a holding in the PGPE portfolio since 2016, and as of May 31, was its second largest investee company.
The company has evolved from a regional packaging business into a full-service CDMO, offering drug development, clinical trial supply, biologics, and sterile fill-finish services, Partners Group said.
The company said it will continue to back PCI’s expansion strategy, which includes investment in specialised capabilities to reinforce the company’s position in the growing pharmaceutical outsourcing market.
The transaction is expected to close in the second half of 2025, subject to regulatory approvals.
Shares in Partners Group Holdings were 1.1% higher at fr.1,070.50 in Zurich on Tuesday morning. Shares in Partners Group Private Equity were 1.5% lower at 834.20 pence in London.
Copyright 2025 Alliance News Ltd. All Rights Reserved.